These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 9794505)
1. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Hashimoto Y; Sasa H; Shimomura M; Inui K Pharm Res; 1998 Oct; 15(10):1609-13. PubMed ID: 9794505 [TBL] [Abstract][Full Text] [Related]
2. Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. Shimomura M; Masuda S; Saito H; Sakamoto S; Uemoto S; Tanaka K; Inui K J Surg Res; 2002 Apr; 103(2):215-22. PubMed ID: 11922737 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction. Okabe H; Yano I; Hashimoto Y; Saito H; Inui K J Pharm Pharmacol; 2002 Jan; 54(1):65-70. PubMed ID: 11829131 [TBL] [Abstract][Full Text] [Related]
4. Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. Yokomasu A; Yano I; Sato E; Masuda S; Katsura T; Inui K Drug Metab Pharmacokinet; 2008; 23(6):469-75. PubMed ID: 19122342 [TBL] [Abstract][Full Text] [Related]
5. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Floren LC; Bekersky I; Benet LZ; Mekki Q; Dressler D; Lee JW; Roberts JP; Hebert MF Clin Pharmacol Ther; 1997 Jul; 62(1):41-9. PubMed ID: 9246018 [TBL] [Abstract][Full Text] [Related]
6. [Therapeutic drug monitoring of immunosuppresants]. Hashida T; Inui K Rinsho Byori; 2001 Jul; 49(7):662-4. PubMed ID: 11519126 [TBL] [Abstract][Full Text] [Related]
7. Decreased oral absorption of cyclosporine A after liver ischemia-reperfusion injury in rats: the contribution of CYP3A and P-glycoprotein to the first-pass metabolism in intestinal epithelial cells. Ikemura K; Urano K; Matsuda H; Mizutani H; Iwamoto T; Okuda M J Pharmacol Exp Ther; 2009 Jan; 328(1):249-55. PubMed ID: 18842703 [TBL] [Abstract][Full Text] [Related]
8. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Masuda S; Uemoto S; Goto M; Fujimoto Y; Tanaka K; Inui K Clin Pharmacol Ther; 2004 Apr; 75(4):352-61. PubMed ID: 15060513 [TBL] [Abstract][Full Text] [Related]
9. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Shimada T; Terada A; Yokogawa K; Kaneko H; Nomura M; Kaji K; Kaneko S; Kobayashi K; Miyamoto K Transplantation; 2002 Nov; 74(10):1419-24. PubMed ID: 12451243 [TBL] [Abstract][Full Text] [Related]
10. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420 [TBL] [Abstract][Full Text] [Related]
11. Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). Qin XL; Bi HC; Wang XD; Li JL; Wang Y; Xue XP; Chen X; Wang CX; Xu le J; Wang YT; Huang M Int J Pharm; 2010 Apr; 389(1-2):114-21. PubMed ID: 20097278 [TBL] [Abstract][Full Text] [Related]
12. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. Hebert MF; Fisher RM; Marsh CL; Dressler D; Bekersky I J Clin Pharmacol; 1999 Jan; 39(1):91-6. PubMed ID: 9987705 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of lower maintenance dose of tacrolimus in obese patients. Sawamoto K; Huong TT; Sugimoto N; Mizutani Y; Sai Y; Miyamoto K Drug Metab Pharmacokinet; 2014; 29(4):341-7. PubMed ID: 24670405 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction. Okabe H; Hashimoto Y; Inui KI J Pharm Pharmacol; 2000 Dec; 52(12):1467-72. PubMed ID: 11197074 [TBL] [Abstract][Full Text] [Related]
15. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Chiou WL; Chung SM; Wu TC Pharm Res; 2000 Feb; 17(2):205-8. PubMed ID: 10751036 [TBL] [Abstract][Full Text] [Related]
16. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Masuda S; Uemoto S; Hashida T; Inomata Y; Tanaka K; Inui K Clin Pharmacol Ther; 2000 Jul; 68(1):98-103. PubMed ID: 10945321 [TBL] [Abstract][Full Text] [Related]
17. Hepatic extraction of tacrolimus in rats with experimental liver diseases. Sasa H; Hashimoto Y; Shimizu T; Inui K Biol Pharm Bull; 1998 Jun; 21(6):610-4. PubMed ID: 9657047 [TBL] [Abstract][Full Text] [Related]
18. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. Saitoh H; Saikachi Y; Kobayashi M; Yamaguchi M; Oda M; Yuhki Y; Achiwa K; Tadano K; Takahashi Y; Aungst BJ Eur J Pharm Sci; 2006 May; 28(1-2):34-42. PubMed ID: 16457995 [TBL] [Abstract][Full Text] [Related]
19. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats. Tian X; Chang Y; Wei J; Liu R; Wang L; Zhang J; Zhang X J Pharm Pharmacol; 2019 May; 71(5):788-796. PubMed ID: 30663770 [TBL] [Abstract][Full Text] [Related]
20. [Effect of genetic polymorphism of cytochrome P450 3A and transporter gene on pharmacokinetics of tacrolimus, a calcineurin inhibitor]. Niwa T; Shiraga T; Omura M; Kondo T; Kuroda M; Takagi A Nihon Yakurigaku Zasshi; 2006 Dec; 128(6):395-404. PubMed ID: 17167213 [No Abstract] [Full Text] [Related] [Next] [New Search]